AustralianSuper Pty Ltd Sells 10,261 Shares of DaVita Inc. $DVA

AustralianSuper Pty Ltd lessened its position in shares of DaVita Inc. (NYSE:DVA) by 8.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 118,037 shares of the company’s stock after selling 10,261 shares during the quarter. AustralianSuper Pty Ltd owned 0.17% of DaVita worth $15,684,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. NewEdge Advisors LLC grew its holdings in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the last quarter. V Square Quantitative Management LLC raised its holdings in shares of DaVita by 22.8% during the 2nd quarter. V Square Quantitative Management LLC now owns 2,422 shares of the company’s stock worth $345,000 after acquiring an additional 449 shares in the last quarter. Truist Financial Corp raised its stake in DaVita by 1.9% during the second quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock valued at $1,232,000 after purchasing an additional 163 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its position in shares of DaVita by 485.5% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 44,809 shares of the company’s stock valued at $6,383,000 after buying an additional 37,156 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DVA stock opened at $107.16 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $179.60. The firm has a market capitalization of $7.57 billion, a PE ratio of 11.04, a P/E/G ratio of 0.65 and a beta of 0.99. The stock’s 50-day simple moving average is $113.80 and its 200-day simple moving average is $125.54.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.59 earnings per share. Sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays cut their target price on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 30th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Truist Financial lowered their price target on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th. Finally, UBS Group reaffirmed a “buy” rating on shares of DaVita in a research report on Monday, December 15th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $145.60.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.